Literature DB >> 12139636

Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.

Pilar Machin1, Lluis Catasus, Cristina Pons, Josefina Muñoz, Jose Maria Conde-Zurita, Judith Balmaña, Maria Barnadas, Rosa M Martí, Jaime Prat, Xavier Matias-Guiu.   

Abstract

BACKGROUND: Muir-Torre syndrome (MTS) is characterized by the co-existence of sebaceous gland tumors of the skin and internal malignancies. Currently, MTS is regarded as a variant of the hereditary non-polyposis colon cancer syndrome (HNPCC). Both MTS and HNPCC are secondary to germline mutations in DNA mismatch repair genes (mainly MSH-2 and MLH-1).
METHODS: Cutaneous (eight sebaceous adenomas, one sebaceous carcinoma and one keratoacanthoma) and internal tumors (four colonic adenocarcinomas, two endometrial carcinomas, two transitional cell carcinomas of renal pelvis and ureter, one adenocarcinoma of the small bowel, one ovarian carcinoma and one colonic tubular adenoma) were obtained from six patients with MTS and were subjected to microsatellite instability (MI) analysis, and to immunostaining for MLH-1 and MSH-2. MI was assessed by evaluating three (CA)n dinucleotide repeats (D2S123, D5S346, D17S250) and the mononucleotide tracts BAT 26 and BAT 25.
RESULTS: All cutaneous and internal tumors exhibited MI. An immunohistochemical concordance between all tumors within each single patient was obtained in five cases. In these five patients all tumors exhibited a lack of MSH-2 staining, consistent with a germline abnormality in this gene. In the one remaining case, the immunohistochemical staining in the sebaceous adenoma was negative for MLH-1 and positive for MSH-2, consistent with a germline alteration in MLH-1. However, the colonic adenocarcinoma in that patient showed positivity for MSH-2 and an equivocal positivity for MLH-1.
CONCLUSIONS: The results confirm that tumors from patients with MTS exhibit MI. Moreover, immunostaining for MLH-1 and MSH-2 may be useful to identify the most probable gene responsible for the disease in each family.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12139636     DOI: 10.1034/j.1600-0560.2002.290705.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  15 in total

1.  Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome.

Authors:  Tristan F P McKnight; Amy E Noffsinger; Kara K Landry; Ovais Ahmed; Rebecca Wilcox
Journal:  Virchows Arch       Date:  2017-05-13       Impact factor: 4.064

2.  Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome.

Authors:  Anu R Lamba; Angela Y Moore; Todd Moore; Jennifer Rhees; Mildred A Arnold; C Richard Boland
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

Review 3.  An Overview of Autosomal Dominant Tumour Syndromes with Prominent Features in the Oral and Maxillofacial Region.

Authors:  Robert A Kennedy; Selvam Thavaraj; Salvador Diaz-Cano
Journal:  Head Neck Pathol       Date:  2017-01-21

Review 4.  DNA repair fidelity in stem cell maintenance, health, and disease.

Authors:  Chinnadurai Mani; P Hemachandra Reddy; Komaraiah Palle
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-04-04       Impact factor: 5.187

Review 5.  Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.

Authors:  Iyer Vishwas Neelakantan; Silvana Di Palma; C E T Smith; A McCoombe
Journal:  Head Neck Pathol       Date:  2015-11-17

6.  Muir-Torre syndrome associated with endometrial carcinoma.

Authors:  Toshimitsu Tohya; Takeshi Ogura; Kengo Nishi; Hazuki Nishi; Kazumi Kuriwaki
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

Review 7.  10 rare tumors that warrant a genetics referral.

Authors:  Kimberly C Banks; Jessica J Moline; Monica L Marvin; Anna C Newlin; Kristen J Vogel
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

8.  Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.

Authors:  Maegan E Roberts; Douglas L Riegert-Johnson; Brittany C Thomas; Colleen S Thomas; Michael G Heckman; Murli Krishna; David J DiCaudo; Alina G Bridges; Katherine S Hunt; Kandelaria M Rumilla; Mark A Cappel
Journal:  J Genet Couns       Date:  2012-12-06       Impact factor: 2.537

9.  Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome.

Authors:  Graça M Dores; Rochelle E Curtis; Jorge R Toro; Susan S Devesa; Joseph F Fraumeni
Journal:  Cancer       Date:  2008-12-15       Impact factor: 6.860

10.  MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.

Authors:  Adisbeth Morales-Burgos; Jorge L Sánchez; Luz D Figueroa; Wilfredo E De Jesús-Monge; Marcia R Cruz-Correa; Carmen González-Keelan; Cruz María Nazario
Journal:  P R Health Sci J       Date:  2008-12       Impact factor: 0.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.